-- Enrollment Complete for MoveDMD® Phase 2 Trial of Edasalonexent, a Potential Disease-Modifying Treatment for Duchenne Muscular Dystrophy (DMD) --
-- Expanding Rare Disease Pipeline with CAT-5571, a Potential Treatment for Cystic Fibrosis --
-- Investor Day Scheduled for November 17 --
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2016 and corporate highlights.
“Catabasis is executing on its mission to bring hope and life-changing therapies to patients and their families suffering from rare diseases”
“Catabasis is executing on its mission to bring hope and life-changing therapies to patients and their families suffering from rare diseases,” said Jill C. Milne, Chief Executive Officer of Catabasis. “We completed enrollment in the Phase 2 portion of the MoveDMD® clinical trial in October and expect to report top-line safety and efficacy results from the placebo-controlled portion of the trial in the first half of Q1 2017; we expect to generate a rich and informative data set in DMD based on the design of the MoveDMD trial including the 36-week open-label extension. We believe in the potential of edasalonexent as monotherapy for the treatment of DMD and also believe that a combination drug approach may be able to offer additional benefits to patients. In addition to our work in DMD, we are evaluating other diseases where the inhibition of NF-kB may be beneficial. There are a number of other rare diseases where NF-kB plays an important role and edasalonexent could have the potential to positively impact patients affected by these diseases. Further, Catabasis recently expanded its rare disease pipeline by adding CAT-5571, an activator of autophagy, as a potential treatment of cystic fibrosis.”
